Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.

Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.